ROS-dependent phosphorylation of Bax by wortmannin sensitizes melanoma cells for TRAIL-induced apoptosis

Cell Death and Disease

Volumn 4, Issue 10, 2013, Pages

  Quast, S A ^a,b   Berger, A ^a,c   Eberle, J ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b FREIE UNIVERSITÄT BERLIN   (Germany)

^c HUMBOLDT UNIVERSITY   (Germany)

Author keywords

Bax; Melanoma; ROS; TRAIL; Wortmannin

Indexed keywords

8 [4 (1 AMINOCYCLOBUTYL)PHENYL] 9 PHENYL 1,2,4 TRIAZOLO[3,4 F][1,6]NAPHTHYRIDIN 3(2H) ONE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PROTEIN BAX; PROTEIN KINASE B INHIBITOR; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 4; SMALL INTERFERING RNA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; WORTMANNIN;

APOPTOSIS; ARTICLE; CELL ACTIVATION; CELL CYCLE; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXICITY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MELANOMA CELL; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SENSITIZATION;

ANDROSTADIENES; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; CASPASES; CELL LINE, TUMOR; ENZYME ACTIVATION; HETEROCYCLIC COMPOUNDS, 3-RING; HUMANS; MELANOMA; MITOCHONDRIA; NADPH OXIDASE; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT; REACTIVE OXYGEN SPECIES; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 84887450014     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2013.344     Document Type: Article

References (61)

1. Krammer PH, Arnold R, Lavrik IN. Life and death in peripheral T cells. Nat Rev Immunol 2007; 7: 532-542
2. Norberg E, Orrenius S, Zhivotovsky B. Mitochondrial regulation of cell death: Processing of apoptosis-inducing factor (AIF). Biochem Biophys Res Co 2010; 396: 95-100
3. Tait SWG, Green DR. Mitochondria and cell death: Outer membrane permeabilization and beyond. Nat Rev Mol Cell Bio 2010; 11: 621-632
4. Fischer U, Janicke RU, Schulze-Osthoff K. Many cuts to ruin: A comprehensive update of caspase substrates. Cell Death Differ 2003; 10: 76-100
5. Chipuk JE, Moldoveanu T, Llambi F, Parsons MJ, Green DR. The BCL-2 family reunion. Mol Cell 2010; 37: 299-310
6. Gillissen B, Wendt J, Richter A, Richter A, Muer A, Overkamp T et al. Endogenous Bak inhibitors Mcl-1 and Bcl-xL: Differential impact on TRAIL resistance in Bax-deficient carcinoma. J.Cell Biol 2010; 188: 851-862
7. Westphal D, Dewson G, Czabotar PE, Kluck RM. Molecular biology of Bax and Bak activation and action. B B A-Mol Cell Res 2011; 1813: 521-531
8. Youle RJ, Strasser A. The BCL-2 protein family: Opposing activities that mediate cell death. Nat Rev Mol Cell Bio 2008; 9: 47-59
9. Walensky LD, Gavathiotis E. BAX unleashed: The biochemical transformation of an inactive cytosolic monomer into a toxic mitochondrial pore. Trends Biochem Sci 2011; 36: 642-652
10. Renault TT, Manon S. Bax: Addressed to kill. Biochimie 2011; 93: 1379-1391
11. Xin MG, Deng XM. Protein phosphatase 2A enhances the proapoptotic function of Bax through dephosphorylation. J Bio Chem 2006; 281: 18859-18867
12. Kim BJ, Ryu SW, Song BJ. JNK-And p38 kinase-mediated phosphorylation of Bax leads to its activation and mitochondrial translocation and to apoptosis of human hepatoma HepG2 cells. J Bio Chem 2006; 281: 21256-21265
13. Shen ZJ, Esnault S, Schinzel A, Borner C, Malter JS. The peptidyl-prolyl isomerase Pin1 facilitates cytokine-induced survival of eosinophils by suppressing Bax activation. Nat Immunol 2009; 10: 257-265
14. Orrenius S. Reactive oxygen species in mitochondria-mediated cell death. Drug Metab Rev 2007; 39: 443-455
15. Franke JC, Plotz M, Prokop A, Geilen CC, Schmalz HG, Eberle J. New caspaseindependent but ROS-dependent apoptosis pathways are targeted in melanoma cells by an iron-containing cytosine analogue. Biochem. Pharmacol 2010; 79: 575-586
16. Morgan MJ, Liu ZG. Reactive oxygen species in TNF alpha-induced signaling and cell death. Mol Cells 2010; 30: 1-12
17. Ashkenazi A. Targeting death and decoy receptors of the tumour-necrosis factor superfamily. Nat Rev Cancer 2002; 2: 420-430
18. Walczak H, Miller RE, Ariail K, Gliniak B, Griffith TS, Kubin M et al. Tumoricidal activity of tumor necrosis factor related apoptosis-inducing ligand in vivo. Nat Med 1999; 5: 157-163
19. Herbst RS, Eckhardt SG, Kurzrock R, Ebbinghaus S, O'Dwyer PJ, Gordon MS et al. Phase I dose-escalation study of recombinant human Apo2L/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancer. J.Clin.Oncol 2010; 28: 2839-2846
20. Soria JC, Mark Z, Zatloukal P, Szima B, Albert I, Juhasz E et al. Randomized Phase II Study of dulanermin in combination with paclitaxel, carboplatin, and bevacizumab in Advanced Non-Small-Cell Lung Cancer. J Clin Oncol 2011; 29: 4442-4451
21. Zhang XD, Wu JJ, Gillespie S, Borrow J, Hersey P. Human melanoma cells selected for resistance to apoptosis by prolonged exposure to tumor necrosis factor-related apoptosisinducing ligand are more vulnerable to necrotic cell death induced by cisplatin. Clin Cancer Res 2006; 12: 1355-1364
22. Kurbanov BM, Fecker LF, Geilen CC, Sterry W, Eberle J. Resistance of melanoma cells to TRAIL does not result from upregulation of antiapoptotic proteins by NF-kappaB but is related to downregulation of initiator caspases and DR4. Oncogene 2007; 26: 3364-3377
23. Flaherty KT, Infante JR, Daud A, Gonzalez R, Kefford RF, Sosman J et al. Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations. New Engl J Med 2012; 367: 1694-1703
24. Dillon RL, Muller WJ. Distinct biological roles for the Akt family in mammary tumor progression. Cancer Res 2010; 70: 4260-4264
25. Aziz SA, Jilaveanu LB, Zito C, Camp RL, Rimm DL, Conrad P et al. Vertical targeting of the phosphatidylinositol-3 kinase pathway as a strategy for treating melanoma. Clin Cancer Res 2010; 16: 6029-6039
26. Sinnberg T, Lasithiotakis K, Niessner H, Schittek B, Flaherty KT, Kulms D et al. Inhibition of PI3K-AKT-mTOR signaling sensitizes melanoma cells to cisplatin and temozolomide. J.Invest Dermatol 2009; 129: 1500-1515
27. Lemke LE, Paine-Murrieta GD, Taylor CW, Powis G. Wortmannin inhibits the growth of mammary tumors despite the existence of a novel wortmannin-insensitive phosphatidylinositol-3-kinase. Cancer Chemoth and Pharm 1999; 44: 491-497
28. Upton JP, Valentijn AJ, Zhang L, Gilmore AP. The N-Terminal conformation of Bax regulates cell commitment to apoptosis. Cell Death Differ 2007; 14: 932-942
29. Berger A, Quast SA, Plotz M, Kammermeier A, Eberle J. Sensitization of melanoma cells for TRAIL-induced apoptosis by BMS-345541 correlates with altered phosphorylation and activation of Bax. Cell Death Dis 2013; 4: E477
30. Quast SA, Berger A, Buttstadt N, Friebel K, Schonherr R, Eberle J. General sensitization of melanoma cells for TRAIL-induced apoptosis by the potassium channel inhibitor TRAM-34 depends on release of SMAC. PLoS One 2012; 7: E39290
31. Ayral-Kaloustian S, Gu JX, Lucas J, Cinque M, Gaydos C, Zask A et al. Hybrid inhibitors of phosphatidylinositol 3-kinase (PI3K) and the mammalian target of rapamycin (mTOR): Design, synthesis, and superior antitumor activity of novel wortmannin-rapamycin conjugates. J Med Chem 2010; 53: 452-459
32. Chen XF, Thakkar H, Tyan F, Gim S, Robinson H, Lee C et al. Constitutively active Akt is an important regulator of TRAIL sensitivity in prostate cancer. Oncogene 2001; 20: 6073-6083
33. Kandasamy K, Srivastava RK. Role of the phosphatidylinositol 30-kinase/PTEN/Akt kinase pathway in tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in non-small cell lung cancer cells. Cancer Res 2002; 62: 4929-4937
34. Hersey P, Zhang XD. Overcoming resistance of cancer cells to apoptosis. J Cell Physiol 2003; 196: 9-18
35. Bozulic L, Hemmings BA. PIKKing on PKB: Regulation of PKB activity by phosphorylation. Curr Opin Cell Biol 2009; 21: 256-261
36. Shi HB, Kong XJ, Ribas A, Lo RS. Combinatorial treatments that overcome PDGFR betadriven resistance of melanoma cells to B-V600E-RAF inhibition. Cancer Res 2011; 71: 5067-5074
37. Sangai T, Akcakanat A, Chen HQ, Tarco E, Wu Y, Do KA et al. Biomarkers of response to Akt inhibitor MK-2206 in breast cancer. Clin Cancer Res 2012; 18: 5816-5828
38. Mochizuki T, Furuta S, Mitsushita J, Shang W, Ito M, Yokoo Y et al. Inhibition of NADPH oxidase 4 activates apoptosis via the AKT/apoptosis signal-regulating kinase 1 pathway in pancreatic cancer PANC-1 cells. Oncogene 2006; 25: 3699-3707
39. Naughton R, Quiney C, Turner SD, Cotter TG. Bcr-Abl-mediated redox regulation of the PI3K/AKT pathway. Leukemia 2009; 23: 1432-1440
40. Bedard K, Krause KH. The NOX family of ROS-generating NADPH oxidases: Physiology and pathophysiology. Physiol Rev 2007; 87: 245-313
41. Min HB, Ghatnekar GS, Ghatnekar AV, You XH, Bu M, Guo XY et al. 2-Methoxyestradiol induced bax phosphorylation and apoptosis in human retinoblastoma cells via p38 MAPK activation. Mol Carcinogen 2012; 51: 576-585
42. Li DC, Ueta E, Kimura T, Yamamoto T, Osaki T. Reactive oxygen species (ROS) control the expression of Bcl-2 family proteins by regulating their phosphorylation and ubiquitination. Cancer Sci 2004; 95: 644-650
43. Verbon EH, Post JA, Boonstra J. The influence of reactive oxygen species on cell cycle progression in mammalian cells. Gene 2012; 511: 1-6
44. Plötz M, Gillissen B, Hossini AM, Daniel PT, Eberle J. Disruption of the VDAC2-Bak interaction by Bcl-xS mediates efficient induction of apoptosis in melanoma cells. Cell Death Differ 2012; 19: 1928-1938
45. Jansen B, Wacheck V, Heere-Ress E, Schlagbauer-Wadl H, Hoeller C, Lucas T et al. Chemosensitization of malignant melanoma by BCL2 antisense therapy. Lancet 2000; 356: 1728-1733
46. Eberle J, Kurbanov BM, Hossini AM, Trefter U, Fecker LF. Overcoming apoptosis deficiency of melanoma-Hope for new therapeutic approaches. Drug Resist Update 2007; 10: 218-234
47. Kaufmann T, Strasser A, Jost PJ. Fas death receptor signalling: Roles of Bid and XIAP. Cell Death Differ 2012; 19: 42-50
48. Berger A, Quast SA, Plotz M, Hein M, Kunz M, Langer P et al. Sensitization of melanoma cells for death ligand-induced apoptosis by an indirubin derivative-enhancement of both extrinsic and intrinsic apoptosis pathways. Biochem Pharmacol 2010; 81: 71-81
49. Song G, Chen GG, Hu T. Lai PBS. Bid stands at the crossroad of stress-response pathways. Curr Cancer Drug Targets 2010; 10: 584-592
50. Hampton MB, Winterbourn CC, Stamenkovic I. Mechanisms of caspase inactivation by hydrogen peroxide. Free Radic Bio Med 1998; 25: S89
51. Borutaite V, Brown GC. Caspases are reversibly inactivated by hydrogen peroxide. FEBS Lett 2001; 500: 114-118
52. Tait SWG, Green DR. Caspase-independent cell death: Leaving the set without the final cut. Oncogene 2008; 27: 6452-6461
53. D'Anneo A, Carlisi D, Lauricella M, Emanuele S, Di Fiore R, Vento R et al. Parthenolide induces caspase-independent and AIF-mediated cell death in human osteosarcoma and melanoma cells. J Cell Physiol 2012; 228: 952-967
54. Hornle M, Peters N, Thayaparasingham B, Vorsmann H, Kashkar H, Kulms D. Caspase-3 cleaves XIAP in a positive feedback loop to sensitize melanoma cells to TRAIL-induced apoptosis. Oncogene 2010; 30: 575-587
55. Li Y, Wang H, Wang Z, Makhija S, Buchsbaum D, LoBuglio A et al. Inducible resistance of tumor cells to tumor necrosis factor-related apoptosis-inducing ligand receptor 2-mediated apoptosis by generation of a blockade at the death domain function. Cancer Res 2006; 66: 8520-8528
56. Ivanov VN, Partridge MA, Johnson GE, Huang SX, Zhou H, Hei TK. Resveratrol sensitizes melanomas to TRAIL through modulation of antiapoptotic gene expression. Exp Cell Res 2008; 314: 1163-1176
57. Jiang CC, Chen LH, Gillespie S, Kiejda KA, Mhaidat N, Wang YF et al. Tunicamycin sensitizes human melanoma cells to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by up-regulation of TRAIL-R2 via the unfolded protein response. Cancer Res 2007; 67: 5880-5888
58. Kurbanov BM, Geilen CC, Fecker LF, Orfanos CE, Eberle J. Efficient TRAIL-R1/DR4-mediated apoptosis in melanoma cells by tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). J Invest Dermatol 2005; 125: 1010-1019
59. Raisova M, Hossini A, Riebeling C, Wieder T, Daniel P, Eberle J et al. Apoptosis resistance in human melanoma cells. J Invest Dermatol 2001; 117: 168
60. Riccardi C, Nicoletti I. Analysis of apoptosis by propidium iodide staining and flow cytometry. Nat Protoc 2006; 1: 1458-1461
61. Eberle J, Fecker LF, Hossini AM, Wieder T, Daniel PT, Orfanos CE et al. CD95/Fas signaling in human melanoma cells: Conditional expression of CD95L/FasL overcomes the intrinsic apoptosis resistance of malignant melanoma and inhibits growth and progression of human melanoma xenotransplants. Oncogene 2003; 22: 9131-9141